Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background and Purpose The detection of aquaporin 4-IgG (AQP4-IgG) is now a critical diagnostic criterion for neuromyelitis optica spectrum disorder (NMOSD). To evaluate the serostatus of NMOSD patients based on the 2015 new diagnostic criteria using a new in-house cell-based assay (CBA). Methods We generated a stable cell line using internal ribosome entry site-containing bicistronic vectors, which allow the simultaneous expression of two proteins (AQP4 and green fluorescent protein) separately from the same RNA transcript. We performed in-house CBA using serum from 386 patients: 178 NMOSD patients diagnosed according to the new diagnostic criteria without AQP4-IgG, 63 high risk NMOSD patients presenting 1 of the 6 core clinical characteristics of NMOSD but not fulfilling dissemination in space, and 145 patients with other neurological diseases, including 66 with multiple sclerosis. The serostatus of 111 definite and high risk NMOSD patients were also tested using a commercial CBA kit with identical serum to evaluate the correlation between the 2 methods. All assays were performed by two independent and blinded investigators. Results Our in-house assay yielded a specificity of 100% and sensitivities of 80% (142 of 178) and 76% (48 of 63) when detecting definite- and high risk NMOSD patients, respectively. The comparison with the commercial CBA kit revealed a correlation for 102 of the 111 patients: no correlation was present in 7 patients who were seronegative using the commercial method but seropositive using the in-house method, and in 2 patients who were seropositive using the commercial method but seronegative using the in-house method Conclusions These results demonstrate that our in-house CBA is a highly specific and sensitive method for detecting AQP4-IgG in NMOSD patients.
Abstract
Background and Purpose The detection of aquaporin 4-IgG (AQP4-IgG) is now a critical diagnostic criterion for neuromyelitis optica spectrum disorder (NMOSD). To evaluate the serostatus of NMOSD patients based on the 2015 new diagnostic criteria using a new in-house cell-based assay (CBA). Methods We generated a stable cell line using internal ribosome entry site-containing bicistronic vectors, which allow the simultaneous expression of two proteins (AQP4 and green fluorescent protein) separately from the same RNA transcript. We performed in-house CBA using serum from 386 patients: 178 NMOSD patients diagnosed according to the new diagnostic criteria without AQP4-IgG, 63 high risk NMOSD patients presenting 1 of the 6 core clinical characteristics of NMOSD but not fulfilling dissemination in space, and 145 patients with other neurological diseases, including 66 with multiple sclerosis. The serostatus of 111 definite and high risk NMOSD patients were also tested using a commercial CBA kit with identical serum to evaluate the correlation between the 2 methods. All assays were performed by two independent and blinded investigators. Results Our in-house assay yielded a specificity of 100% and sensitivities of 80% (142 of 178) and 76% (48 of 63) when detecting definite- and high risk NMOSD patients, respectively. The comparison with the commercial CBA kit revealed a correlation for 102 of the 111 patients: no correlation was present in 7 patients who were seronegative using the commercial method but seropositive using the in-house method, and in 2 patients who were seropositive using the commercial method but seronegative using the in-house method Conclusions These results demonstrate that our in-house CBA is a highly specific and sensitive method for detecting AQP4-IgG in NMOSD patients.
참고문헌 (27)
- Lennon VA, "A serum autoantibody marker of neuromyelitis optica:distinction from multiple sclerosis", Lancet, 364, pp.2106~2112 (2004)
- Lennon VA, "IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4water channel", J Exp Med, 202, pp.473~477 (2005)
- Roemer SF, "Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis", Brain, 130, pp.1194~1205 (2007)
- Bradl M, "Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo", Ann Neurol, 66, pp.630~643 (2009)
- Hinson SR, "Neurological autoimmunity targeting aquaporin-4", Neuroscience, 168, pp.1009~1018 (2010)
- Verkman AS, "Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO", Brain Pathol, 23, pp.684~695 (2013)
- Wingerchuk DM, "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders", Neurology, 85, pp.177~189 (2015)
- Waters PJ, "Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays", Neurology, 78, pp.665~671 (2012)
- Polman CH, "Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria", Ann Neurol, 69, pp.292~302 (2011)
- Waters P, "Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica", J Neurol Neurosurg Psychiatry, 87, pp.1005~1015 (2016)
- Hinson SR, "Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes", Proc Natl Acad Sci U S A, 109, pp.1245~1250 (2012)
- Kalluri SR, "Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica", Arch Neurol, 67, pp.1201~1208 (2010)
- Jarius S, "Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature", Brain Pathol, 23, pp.661~683 (2013)
- Mader S, "Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica", PLoS One, 5, pp.e10455~ (2010)
- Pisani F, "Aquaporin-4 autoantibodies in neuromyelitis optica: AQP4isoform-dependent sensitivity and specificity", PLoS One, 8, pp.e79185~ (2013)
- Kitley J, "Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO", Neurol Neuroimmunol Neuroinflamm, 2, pp.e121~ (2015)
- Crane JM, "Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1", M23 isoforms and orthogonal arrays, 2011, pp.286, 16516~16524
- Iorio R, "Astrocytic autoantibody of neuromyelitis optica (NMO-IgG)binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays", J Autoimmun, 40, pp.21~27 (2013)
- Sato DK, "Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders", Neurology, 80, pp.2210~2216 (2013)
- Marignier R, "Aquaporin-4 antibody-negative neuromyelitis optica:distinct assay sensitivity-dependent entity", Neurology, 80, pp.2194~2200 (2013)
- Rossi A, "Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1", M23 isoform content, or supramolecular assembly, 2012, pp.60, 2027~2039
- Nicchia GP, "Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies", Glia, 57, pp.1363~1373 (2009)
- Tuller F, "Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders", J Neuroinflammation, 13, pp.176~ (2016)
- Kim TK, "Mammalian cell transfection: the present and the future", Anal Bioanal Chem, 397, pp.3173~3178 (2010)
- Chalfie M, "Green fluorescent protein as a marker for gene expression", Science, 263, pp.802~805 (1994)
- Waters PJ, "Evaluation of aquaporin-4 antibody assays", Clin Exp Neuroimmunol, 5, pp.290~303 (2014)
- Gurtu V, "IRES bicistronic expression vectors for efficient creation of stable mammalian cell lines", Biochem Biophys Res Commun, 229, pp.295~298 (1996)